ALIVE launches new fund to target global HealthTech
The fund, with a total target size of approximately $200 million, aims to invest in advanced-stage digital health companies in Israel and internationally.
The ALIVE fund, managed by founding partners Prof. Rafi Beyar, Prof. Ari Shamiss, Michel Habib, and Dudi Klein, announced the completion of the initial closing of its new ALIVE Growth Fund III and the commencement of investment activity.
The fund, with a total target size of approximately $200 million, will focus on investments in HealthTech and digital health companies at advanced growth stages, both in Israel and internationally.
1 View gallery
ALIVE management (from left): Michel Habib, Prof. Ari Shamiss, Prof. Rafi Beyar, Dudi Klein
(Nir Slakman)
The ALIVE fund operates based on strategic partnerships with leading healthcare organizations in Israel and around the world, including the Maccabi and Assuta groups, and the Carilion Hospital Group in the United States. Together with anchor financial investors, including Leumi Partners and Menoraת who have continued their commitment to the ALIVE VC since its first fund, the fund is positioned to execute its investment strategy: leading investments in groundbreaking health-tech companies poised for growth in global markets.
The current fundraising builds on the success of the previous funds, ALIVE Fund I and ALIVE Next Fund II, which over the past five years have recorded three exits among their portfolio companies, including the sale of Innovalve to Edwards and the sale of Cynerio to Axonius.
